Key facts
- Engitix’s last known valuation is $15.0M (Jan 2026).
- It has raised $118.2M; the latest was Later Stage VC ($25.0M) in Dec 2025.
- Notable investors include Dompé, LabCentral, Netherton Investments, UCL Business, University College London.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Engitix
- ·The full record, as it builds
Funding rounds
No funding rounds for Engitix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Engitix
Developer of a therapeutic discovery platform designed to develop predictive models of human biology using the extracellular matrix. The company offers human-derived extracellular matrix scaffolds, advanced computational tools, and three-dimensional translational systems, enabling pharmaceutical researchers and healthcare developers to create safer and more effective therapies for chronic and life-threatening diseases.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2016
- Employees
- 61
- Website
- engitix.com/
- Ownership
- Privately Held (backing)
Engitix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Engitix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Engitix in its N-PORT filings yet. We sweep new filings monthly.